Mesoblast limited (MESO) Expected to Post Quarterly Sales of $6.36 Million

Analysts expect that Mesoblast limited (NASDAQ:MESO) will report sales of $6.36 million for the current fiscal quarter, Zacks reports. Two analysts have made estimates for Mesoblast’s earnings. The highest sales estimate is $11.10 million and the lowest is $1.61 million. Mesoblast reported sales of $13.40 million during the same quarter last year, which indicates a negative year-over-year growth rate of 52.5%. The firm is scheduled to announce its next earnings report on Tuesday, February 26th.

On average, analysts expect that Mesoblast will report full year sales of $16.58 million for the current fiscal year, with estimates ranging from $6.80 million to $25.50 million. For the next fiscal year, analysts anticipate that the business will post sales of $48.44 million, with estimates ranging from $11.20 million to $85.67 million. Zacks’ sales calculations are an average based on a survey of sell-side research analysts that cover Mesoblast.

Mesoblast (NASDAQ:MESO) last released its quarterly earnings results on Thursday, November 15th. The company reported ($0.20) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.24) by $0.04. The company had revenue of $11.64 million during the quarter, compared to analysts’ expectations of $1.03 million. Mesoblast had a negative net margin of 171.79% and a negative return on equity of 12.90%.



Several research analysts have recently weighed in on the stock. HC Wainwright set a $17.00 price target on shares of Mesoblast and gave the company a “buy” rating in a report on Thursday, October 25th. Zacks Investment Research raised shares of Mesoblast from a “hold” rating to a “buy” rating and set a $5.00 price objective on the stock in a research report on Saturday, February 2nd. Maxim Group set a $16.00 price target on shares of Mesoblast and gave the stock a “buy” rating in a research report on Monday, November 26th. ValuEngine lowered shares of Mesoblast from a “buy” rating to a “hold” rating in a research report on Tuesday, December 18th. Finally, Oppenheimer set a $15.00 price objective on shares of Mesoblast and gave the company a “buy” rating in a research report on Monday, November 12th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. The company has an average rating of “Buy” and an average price target of $11.92.

Several hedge funds have recently added to or reduced their stakes in MESO. Citadel Advisors LLC acquired a new position in shares of Mesoblast in the third quarter valued at about $215,000. Renaissance Technologies LLC grew its stake in shares of Mesoblast by 249.8% in the third quarter. Renaissance Technologies LLC now owns 165,161 shares of the company’s stock valued at $1,348,000 after acquiring an additional 117,951 shares in the last quarter. Capital World Investors acquired a new position in shares of Mesoblast in the third quarter valued at about $3,695,000. Jane Street Group LLC acquired a new position in shares of Mesoblast in the third quarter valued at about $117,000. Finally, Penbrook Management LLC grew its stake in shares of Mesoblast by 6.2% in the fourth quarter. Penbrook Management LLC now owns 240,900 shares of the company’s stock valued at $993,000 after acquiring an additional 14,000 shares in the last quarter. Institutional investors and hedge funds own 3.01% of the company’s stock.

Shares of Mesoblast stock traded up $0.04 on Wednesday, hitting $4.31. The company had a trading volume of 37,970 shares, compared to its average volume of 36,903. The stock has a market capitalization of $402.11 million, a PE ratio of -6.84 and a beta of 1.74. Mesoblast has a twelve month low of $3.35 and a twelve month high of $8.78. The company has a quick ratio of 3.57, a current ratio of 3.57 and a debt-to-equity ratio of 0.12.

Mesoblast Company Profile

Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage adult stem cells. The company's products under the Phase III clinical trials include MSC-100-IV for steroid refractory acute graft versus host disease; MPC-150-IM for advanced heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease.

Featured Article: The Role of a Fiduciary and Individual Investors

Get a free copy of the Zacks research report on Mesoblast (MESO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Mesoblast (NASDAQ:MESO)

Receive News & Ratings for Mesoblast Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mesoblast and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply